<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> is associated with 25% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In the <z:mp ids='MP_0001845'>inflammation</z:mp>-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> axis, <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E(2) (<z:chebi fb="0" ids="26338">PGE</z:chebi>(2)) is one of the major players </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="26338">PGE</z:chebi>(2) synthases (PGES) are the enzymes downstream of the cyclooxygenases (COXs) in the <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) biosynthesis pathway </plain></SENT>
<SENT sid="3" pm="."><plain>Microsomal <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E(2) synthase 1 (mPGES-1) is inducible by pro-inflammatory stimuli and constitutively expressed in a variety of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The potential role for this enzyme in <z:mp ids='MP_0002006'>tumorigenesis</z:mp> has been reported and mPGES-1 represents a novel therapeutic target for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In order to identify novel small molecule inhibitors of mPGES-1, we screened the ChemBridge library and identified 13 compounds as potential hits </plain></SENT>
<SENT sid="6" pm="."><plain>These compounds were tested for their ability to bind directly to the enzyme using surface plasmon resonance spectroscopy and to decrease cytokine-stimulated <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) production in various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines </plain></SENT>
<SENT sid="7" pm="."><plain>We demonstrate that the compound PGE0001 (ChemBridge ID number 5654455) binds to human mPGES-1 recombinant protein with good affinity (K(D) = 21.3 ± 7.8 μM) </plain></SENT>
<SENT sid="8" pm="."><plain>PGE0001 reduces IL-1β-induced <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) release in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HCA</z:e>-7 colon and A549 <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> cell lines with EC(50) in the sub-micromolar range </plain></SENT>
<SENT sid="9" pm="."><plain>Although PGE0001 may have alternative targets based on the results from in vitro assays, it shows promising effects in vivo </plain></SENT>
<SENT sid="10" pm="."><plain>PGE0001 exhibits significant anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity in SW837 rectum and A549 <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> xenografts in <z:mp ids='MP_0002536'>SCID</z:mp> mice </plain></SENT>
<SENT sid="11" pm="."><plain>Single injection i.p. of PGE0001 at 100 mg/kg decreases serum <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) levels in mice within 5 h </plain></SENT>
<SENT sid="12" pm="."><plain>In summary, our data suggest that the identified compound PGE0001 exerts anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity via the inhibition of the <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) synthesis pathway </plain></SENT>
</text></document>